The Zimulti Acomplia Report

Now that a promising new prescription weight loss drug, rimonabant, it is today available in the U.K., Germany and 44 other countries, the launch of the most anticipated weight-loss Drug since Fen-phen is generating a great deal of excitement among millions of obese people  and seriously overweight Americans and Europeans.
The medication, sold in Europe as Acomplia, may ultimately be sold in the United States as Zimulti — but that day seems to be  several years off after an FDA advisory panel voted against sale of rimonabant in summer 2007 out of concern over its depressive side effects.
The Rimonabant Zimulti Acomplia Report, updated every day, will track the continuing efforts of Sanofi Avensis to get Rimonabant approved for sale on the U.S. market The Zimulti Acomplia Report also will provide news,informations and reviews about  rimonabant so those eager to try this new anti-obesity drug will have the latest information on availability, weight-loss results and side-effects.
Side effects of Acomplia Rimonabant were described as minor and temporary, the most frequent    being diarrhea, nausea, vomiting and dizziness. More severe anticipated side effects, especially    depression, did not materialize. it caused  nausea in 13% of patients, vs. in 4% of those who got    placebo.